First human trial begins for new vaccine against severe diarrhea
NCT ID NCT07205926
Summary
This is the first human study of a new vaccine called IVT Shigella-04, designed to prevent Shigella infections that cause severe diarrhea. Researchers will test five different dose levels in 60 healthy adults aged 18-49 to see if the vaccine is safe and triggers a protective immune response. Participants will receive two injections 28 days apart, and their health will be closely monitored for six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHEA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medpace Clinical Pharmacology Unit
RECRUITINGCincinnati, Ohio, 45227, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.